A few reasons why Riskpro should be your choice. Firstly, Risk Management is our only focus. Doing one thing every day makes us good at what we do. Secondly, our fees are very competitive and well below the larger consulting firms. We can use a dynamic pool of resources to ensure a cost-effective solution.
ESG needs to be adhered to both by large companies and smaller ones who supply to them or who export to the western economies where the government, investors as well as the general public is concerned about sustainability. Already companies have been asked by their buyer to give their compliance reports.
The manner of reporting, adherence to standards and avoidance of greenwashing is now an important thing and businesses need to start working towards their sustainability reporting. This webinar will cover ESG Reporting and how it needs to be approached.
The CANHEART ‘big data’ research initiative is aimed at measuring and improving cardiovascular health and the quality of ambulatory cardiovascular care provided in Ontario, Canada using the population-based CANHEART cohorts. The CANHEART cohorts were created through the linkage of 19+ routinely collected health administrative, vital statistics, survey and laboratory databases housed at ICES. The strength of these cohorts lies in the large sample size, containing information on 9.8 million Ontarians age 20-105 years, and diversity of the linked databases.
Building upon the insights gained to date through the CANHEART work, we have recently launched a new CANHEART SPOR project aimed at leveraging big data to conduct innovative cardiovascular clinical trials. We aim to: 1) undertake a pragmatic cluster randomized registry-based clinical trial to improve lipid-management amongst intermediate-and high-risk patients residing in high-risk health regions in Ontario (called CHOICES), and 2) develop novel algorithms for measuring clinical outcomes in clinical trials using health-related databases and compare whether they are as accurate as traditional event ascertainment methods in a prospective clinical trial (called INVESTED). These projects will be undertaken by an interdisciplinary team consisting of experts in administrative health databases, implementation science, clinical trials, knowledge translation and patient engagement.
EuSpRIG is a voluntary and non-profit organisation. Whatever your interest in Spreadsheet Risk Management, we would be pleased to hear from you and welcome any and every contribution.
Guided by the risk information-seeking and processing model, this study examines positive and negative affect separately in their influence on information-seeking intentions and avoidance through structural equation analyses. The highlight is that information avoidance seems to be driven by positive affect, while information seeking seems to be more heavily influenced by negative affect. Another interesting finding is that informational subjective norms are positively related to both seeking and avoidance, which suggests that one’s social environment has the potential to strongly influence the way he or she handles climate change information. Implications for theory and practice are discussed.
Researchers repeatedly discovered primary pharmaceutical contaminants, their metabolites, and transformation products in aquatic ecosystems. Body metabolism may not convert consumed pharmaceuticals to their metabolic elements before excretion. In this case, clinical and industrial wastes ensure their presence in the environment. Nevertheless, conventional wastewater treatment methods are ineffective for removing pharmaceutical wastes. Once in the ecosystem, they alter the physiological response of nontarget exposed aquatic and even terrestrial organisms due to induced toxicity.
IT involves the search for new opportunities through the introduction of new products into new markets. This kind of diversification strategy is one of the most risky and costly for company.
Five years ago, around Christmas 2012, I wrote an article about Cynefin, the sensemaking framework. I focused it on software development, because that was the main industry I worked in, and particularly focused on using it to work out which of our requirements were complex, so that we could embrace uncertainty and risk, and avoid…
If an organization really wants to empower its users, it needs a way to provide maximum power to the user with both safety and security. APIs allow you to design a solution that's not simply the average of these extremes, but rather provides 90% of the power with 99% of the security.
K. Wilson, und S. Hawken. Pharmacoepidemiology and drug safety, 22 (1):
108-10(Januar 2013)6932<br/>JID: 9208369; aheadofprint;<br/>Tipus d'estudis; Self controlled case series; Tamaño del efecto; Risc relatiu vs absolut.
G. Smith. Journal of epidemiology and community health, 60 (5):
382-8(Mai 2006)4828<m:linebreak></m:linebreak>JID: 7909766; 57-88-5 (Cholesterol); 9001-32-5 (Fibrinogen); ppublish;<m:linebreak></m:linebreak>Epidemiologia genètica.
M. Bobbio, B. Demichelis, und G. Giustetto. Lancet, 343 (8907):
1209-11(Mai 1994)6680<m:linebreak></m:linebreak>LR: 20071115; JID: 2985213R; OID: KIE: 43813; OTO: KIE; GN: KIE: KIE BoB Subject Heading: human experimentation/research design; GN: KIE: KIE BoB Subject Heading: patient care/drugs; GN: KIE: Full author name: Bobbio, Marco; GN: KIE: Full author name: Demichelis, Brunella; GN: KIE: Full author name: Giustetto, Guido; ppublish;<m:linebreak></m:linebreak>Presentació de dades.
K. Flegal, B. Graubard, und D. Williamson. American journal of epidemiology, 160 (4):
331-8(August 2004)4391<m:linebreak></m:linebreak>LR: 20041117; PUBM: Print; JID: 7910653; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.
G. Siontis, und J. Ioannidis. International journal of epidemiology, 40 (5):
1292-307(Oktober 2011)6416<m:linebreak></m:linebreak>JID: 7802871; 2011/07/06 aheadofprint; ppublish;<m:linebreak></m:linebreak>Tamaño del efecto; Interpretació de resultats.
H. Kim. Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (2 Pt 1):
559-65(Januar 2007)4698<m:linebreak></m:linebreak>LR: 20071203; GR: AI 029530/AI/NIAID NIH HHS/United States; GR: HL 070149/HL/NHLBI NIH HHS/United States; JID: 9502500; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
P. Andersen, und N. Keiding. Statistics in medicine, 31 (11-12):
1074-88(Mai 2012)6439<m:linebreak></m:linebreak>CI: Copyright (c) 2011; JID: 8215016; aheadofprint;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
L. Mell, und J. Jeong. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (28):
4297-9(Oktober 2010)Comparacions múltiples.